In a report released on October 27, Brian Skorney from Robert W. Baird maintained a Buy rating on Eiger Biopharmaceuticals (EIGR – Research Report), with a price target of $29.00. The company’s shares closed last Friday at $5.12.
According to TipRanks, Skorney is an analyst with an average return of -5.3% and a 44.47% success rate. Skorney covers the Healthcare sector, focusing on stocks such as Eiger Biopharmaceuticals, Amgen, and Biogen.
Eiger Biopharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $35.00.
See today’s best-performing stocks on TipRanks >>
Based on Eiger Biopharmaceuticals’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $4.09 million and a GAAP net loss of $21.88 million. In comparison, last year the company earned a revenue of $2.1 million and had a GAAP net loss of $19.17 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Eiger BioPharmaceuticals, Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of well-characterized drugs for life-threatening, rare and ultra-rare diseases with high unmet medical needs and no approved therapies. The company was founded by David A. Cory on November 6, 2008 and is headquartered in Palo Alto, CA.
Read More on EIGR:
